You need …
- a medical writer with excellent writing skills and attention to detail
- a trainer, experienced in science education
- a comprehensive, critical look at the scientific evidence
- a consultant
- a fresh perspective
I offer …
- medical and scientific writing, medical communications, and training, as well as in-depth analyses of scientific evidence
- more than 15 years of relevant professional experience
- a network of native English and German medical writers and a graphic designer to ensure all materials follow the highest standards
Services
Medical & Scientific Writing
Publication Planning, Data Interpretation, Medical & Scientific Writing, and Submission Support – let me provide the all-round carefree package!
My personal experience extends over several therapeutic areas, such as oncology and hematology, nephrology, neurology, and immunology. In addition, I will to dig into any new field to help you get your data published.
I will comply with any guidelines or standard operating procedures your institution may adhere to.
- Primary manuscripts, review articles, and case reports
- Abstracts and posters
- Books and book chapters
- Product monographs
- Slide presentations
- Congress reports
- Symposia booklets and proceedings
- Meeting protocols
- Press releases
- … and more
Educational Writing & Scientific Training
Training materials and training sessions – let me train you and your staff!
With my writing experience combined with a certified trainer background, I will develop your educational materials and provide training to your new hires, sales force, RMLs, and other staff.
- Materials for physicians
- Training material and on-site training for medical representatives, RMLs, etc
- Newsletters
- Product monographs
- Books and book chapters
- Publications supported by an educational grant
- … and more
Medical Communications
Strategic, multi-channel communication of your latest science – let me get your message across!
I offer strategic communication plans and materials for your product and/or therapeutic area and will be able to develop the respective content in close collaboration with your scientific and commercial teams.
I will comply with any guidelines or standard operating procedures your institution may adhere to.
- Slide decks
- Frequently Asked Questions (FAQs)
- Objection handlers
- Newsletters
- Highlight Reports
- Satellite symposia (content only)
- Symposia booklets and proceedings
- Medical affairs booth materials
- Product monographs
- … and more
Consultancy
A diverse background, combined with out-of-the-box thinking – let me take you further!
Do you need an in-depth analysis of the published scientific evidence of a drug or research question?
Do you need an estimate of the market potential of a new drug and its competitive situation?
Or maybe you need a regular update of the literature for a specific topic of interest?
Or you need to fill a temporary gap or are short in resources?
Please ask for a no-obligation discussion.
- Business opportunity evaluations
- Competitive Intelligence reports
- Literature research
- Literature summaries and analyses
- Frequently Asked Questions (FAQs)
- Objection Handlers
- … and more
↑
Work Samples & References
Work Samples
Articles published under own name
Pronai W, Rosenkranz AR, Bock A, Klauser-Braun R, Jäger C, Pendl G, Hemetsberger M, Lhotta K.
→ Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. Wien Klin Wochenschr. 2017 May;129(9-10):317-328.
Weitgasser R, Ratzinger M, Hemetsberger M, Siostrzonek P.
→ LDL-cholesterol and cardiovascular events: the lower the better? Wien Med Wochenschr. 2016 Oct 21. [Epub ahead of print]
Rosenberger J, Mierzicki P, Selyutin A, Svara F, Hemetsberger M.
→ WELCOME - Web-Based Evaluation of the Clinical Bene t of Cinacalcet (MIM) in End-Stage Renal Disease (ESRD) in Central and Eastern Europe (CEE). J Am Soc Nephrol 27, 2016: 855A. Abstract SA-PO962 and Poster.
Brodowicz T, Hemetsberger M, Windhager R.
→ Denosumab for the treatment of giant cell tumor of the bone. Future Oncol. 2015;11(13):1881-94.
Hemetsberger M, Oberbauer R, Erb H, Pronai W.
→ EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice. Wien Med Wochenschr. 2015 Oct;165(19-20):410-8.
Pronai W, Neyer U, Barnas U, Wieser C, Jaeger C, Dekic D, Hemetsberger M, Rosenkranz AR.
→ Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE. Wien Med Wochenschr. 2014 Mar;164(5-6):109-19
Friedl C, Hemetsberger M, Mader J, Fahrleitner-Pammer A, Pieber TR, Rosenkranz AR.
→ Awareness of chronic kidney disease in Austria: a frequently under-recognized clinical picture. Wien Klin Wochenschr. 2013 Jul;125(13-14):362-7
Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR.
→ The MAINTAIN study-managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. Wien Klin Wochenschr. 2013 Feb;125(3-4):71-82
Writing and/or editorial support – full manuscripts
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.
→ Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print]
Uitz E, Tonninger-Bahadori K, Nekrep K, Bahadori B.
→ The effect of Lactobacillus casei rhamnosus (LCR35) supplementation on the adherence, tolerance and efficacy of Helicobacter pylori therapy: an open-label, observational, non-interventional, multicenter pilot study. International Journal of Probiotics and Prebiotics Vol. 12, No. 4, pp. 159-166, 2017
Boschitsch EP, Durchschlag E, Dimai HP.
→ Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic. Climacteric. 2017 Apr;20(2):157-163.
Haymerle G, Fochtmann A, Kunstfeld R, Pammer J, Erovic BM.
→ Merkel cell carcinoma: Overall survival after open biopsy versus wide local excision. Head Neck. 2016 Apr;38 Suppl 1:E1014-8.
Mądry R, Popławska L, Haslbauer F, Šafanda M, Ghizdavescu D, Benkovicova J, Csőszi T, Mihaylov G, Niepel D, Jaeger C, Frkanova I, Macovei A, Staudigl C.
→ Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr. 2016 Apr;128(7-8):238-47.
Mihaylov G, Mihaylova Z, Drgona L, Cipkova A, Novak J, Petrova R.
→ Healthcare resource utilization and G-CSF use in patients with solid tumors or hematological malignancies hospitalized for febrile neutropenia in Bulgaria, Czech Republic and Slovakia. memo. 2016 Sep;9:144–152
Lakomy R, Rogowski W, Piko B, Mihaylova Zh, Pritzova E, Kvocekova L.
→ Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study. Cancer Manag Res. 2015 Oct 23;7:311-8.
Kunstfeld R.
→ Therapiestrategien im Überblick: Das Basalzellkarzinom. Spektrum Dermatologie 01|2015
Kunstfeld R.
→ Aktinische Keratosen. Spektrum Dermatologie 01|2015
Dreier J, Dummer R, Felderer L, Nägeli M, Gobbi S, Kunstfeld R.
→ Emerging drugs and combination strategies for basal cell carcinoma. Expert Opin Emerg Drugs. 2014 Sep;19(3):353-65.
Fochtmann A, Haymerle G, Kunstfeld R, Pammer J, Grasl MCh, Erovic BM.
→ Prognostic significance of lymph node ratio in patients with Merkel cell carcinoma. Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1777-83.
Bach V., Schruckmayer G., Sam I., Kemmler G., Stauder R.
→ Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging. 2014 Jul 22;9:1187-96.
Kunstfeld R.
→ Smoothened inhibitors in the treatment of advanced basal cell carcinomas. Curr Opin Oncol. 2014 Mar;26(2):184-95
Hilbe W, Abacioglu U, Aebersold DM, Bachouchi M, Brodowicz T, Gaafar R, Holzer G, Mohn-Staudner A, Kalev D, Kalinka-Warzocha E, Kovac V, Siano M, Yumuk F, Tamasi L.
→ CECOG experts’ recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. memo – Magazine of European Medical Oncology 2013;2:75-82
Anghel R, Bachmann A, Bekşac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Lang I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C.
→ Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr. 2013 Aug;125(15-16):439-47
Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D.
→ Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer. 2013 Nov;21(11):3085-93
Valentiny C, Mitrovic M, Pleyer L, Steurer M, Willenbacher W, Stauder R.
→ Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. Wien Klin Wochenschr. 2013 Jan;125(1-2):50-3
Wieser C, Rosenkranz AR.
→ Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J 2013;6(5):539-542
Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, Jaeger C.
→ RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin 2011;27(2):355-63
Zitt E, Jäger C, Rosenkranz AR, Eigner M, Kodras K, Kovarik J, Graf H, Pétavy F, Horn S, Watschinger B.
→ Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients - Results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr 2011;123(1-2):45-52
Writing and/or editorial support – conference abstracts and posters
Hebart H, Tomasek J, Csoszi T, Koukakis R, Kafatos G, Kuhn A, Bjorklof K, Buchler T.
→ Clinical practice use of panitumumab combined with chemotherapy in patients with wild-type RAS metastatic colorectal cancer. 2018 Gastrointestinal Cancers Symposium, Abstract 852 and poster.
Haslbauer F, Petzer A, Safanda M, Tomova A, Porubska M, Bajory Z, Niepel D, Jaeger C, Kalinin D, Greil R.
→ Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: interim analysis. Support Care Cancer. 2017 Jun;25(Suppl 2):S77. Abstract eP037 and Poster.
Rosenberger J, Mierzicki P, Selyutin A, Svara F, Jedynasty K.
→ WELCOME – Web-Based Evaluation of Clinical Benefit of Cinacalcet in End-Stage Renal Disease in Central and Eastern Europe. J Am Soc Nephrol 26, 2015: 205A. Abstract TH-PO520 and Poster.
Irzyniec TJ, Parikova A, Selyutin A, Csiky B, Rosenberger J, Rus I, Jedynasty K.
→ Observational Study on the Use of Darbepoetin Alfa in Hemodialysis Patients in Central Eastern Europe – ANREG Final Analysis. J Am Soc Nephrol 26, 2015: 960A. Abstract PUB315.
Mihaylov G, Kuchma G, Obernauerová J, Skopec B, Sninska Z, Tzvetkov N, Niepel D, Cernelc.
→ An observational clinical practice study of romiplostim in patients with chronic immune thrombocytopenic purpura (ITP) – PLATON interim results. Annual Meeting of the European Hematology Association 2015. Abstract E1415 and Poster.
Irzyniec T, Parikova A, Selyutin A, Csiky B, Rosenberger J, Rus I.
→ Observational study on the use of darbepoetin alfa (DA) in hemodialysis patients in Central Eastern Europe. Annual Meeting of the ERA-EDTA 2015. Abstract FP399 and Poster.
Dittrich C, Kosty M, Jezdic S, et al.
→ ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016 Sep 29;1(5):e000097
Mihaylov G, Mihaylova Z, Drgona L, Cipkova A, Novak J, Petrova R.
→ Health Care Resource Utilization (HCRU) In Hospitalized Febrile Neutropenia (FN) Patients Treated With Chemotherapy for Solid Tumors (ST) And Hematological Malignancies (HM) In Bulgaria (BG), Czech Republic (CZ) And Slovakia (SK) As Observed In Clinical Practice. Value Health. 2014 Nov;17(7):A657-8.
Gercheva L, Goranov S, Raynov J, Mihaylova Z, Mihaylov G, Karanikolov S, Petrova R.
→ Health Care Resource Utilization (HCRU) In Hospitalized Febrile Neutropenia (FN) Patients Treated With Chemotherapy For Solid Tumors (ST) And Hematological Malignancies (HM) In Bulgaria. Value Health. 2014 Nov;17(7):A656.
Eisterer W, Trojan A, Galid A, Haslbauer F, Delmore G, Kolb R, Jaeger C, Bast C, Pezzani I, Schmid M.
→ SOMPAS: A prospective, non-interventional study (NIS) of the management of symptomatic chemotherapy (CT)-induced anemia (CIA) in patients (pts) with colorectal (CRC), breast (BC) or lung cancer (LC) in Austria (AT) and Switzerland (CH). Ann Oncol. 2014 Sep;25(suppl_4):iv528. Abstract 1511P and Poster.
Kolb R, Galid A, Haslbauer F, Jaeger C, Eisterer W.
→ SOMPAS: Eine prospektive, nicht-interventionelle Studie des Managements der symptomatischen Chemotherapie-assoziierten Anämie bei Patienten mit Kolorektal-, Mamma-, oder Lungenkarzinom in Österreich. Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie 2014. Abstract and Poster.
Vavra C, Singer C, Staudigl C, Hubalek M, Unterrieder K, Jaeger C, Sevelda P.
→ G-CSF Prophylaxe bei Hochrisikopatientinnen mit soliden Tumoren in der klinischen Praxis: IMPACT SOLID Studie. Wissenschaftliche Tagung der Arbeitsgruppe der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe 2012. Abstract and Poster.
Neumeister P, Gaiger A, Keil F, Ulsperger E, Weidinger G, Greil R, Bendall K, Jaeger C.
→ G-CSF primary prophylaxis (PP) and neutropenia-related outcomes by age in patients with non-Hodgkins lymphoma (NHL) receiving R-CHOP-21: Austrian results from the international IMPACT NHL study. Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie 2013. Abstract and Poster.
Commissioned articles
Advisory Board Report, Amgen GmbH, Vienna, Austria
→ Knochenveränderungen beim nephrologischen Patienten: Diagnose und Therapie mit Fokus auf Cinacalcet, Nephro-News 1/12, print edition
Medical communications
Influenza vaccination campaign, Federal Office of Public Health, Berne, Switzerland
→ Grippe? Impfen macht Sinn. Eine Information für Fachpersonen im Gesundheitswesen.
→ Antworten auf häufig gestellte Fragen zur saisonalen Grippe
→ Nationale Grippepräventionskampagne 2001–2007. Entwicklungsverlauf der Durchimpfung der Personen ab 65 Jahre
→ Nationale Strategie zur Grippeimpfpromotion 2008–2012
Papers
C. Hametner, M. Hemetsberger, M. Treu, K. Mereiter, U. Jordis, J. Fröhlich.
Addition of nucleophiles to immonium galanthamines. European Journal of Organic Chemistry 2005:2:404 - 409.
M. Hemetsberger, M. Treu, C. Hametner, U. Jordis, K. Mereiter, J. Fröhlich.
1,3-Dipolar cycloaddition reactions to galanthamine nitrone: An entry to 4a,5,9,10-tetrahydro-6H,14aH-benzofuro[3a,3,2-ef]isoxazolo[3,2-a][2]benzazepines. Heterocycles 2004;63(10):2217 - 2224.
M. Hemetsberger, M. Treu, U. Jordis, K. Mereiter, C. Hametner, J. Fröhlich.
1-Methylgalanthamine Derivates. Monatshefte für Chemie/Chemical Monthly 2004;135(10):1275 - 1287.
Abstracts, oral and poster presentations
J. Fröhlich, U. Jordis, M. Hemetsberger, L. Czollner, B. Küenburg.
Galanthamine, an Amaryllidaceae Alkaloid for the Treatment of Alzheimer's Desease: Technical Synthesis, Novel Active Derivates Therof and Structure Activity Studies. Oral presentation at the Eleventh FECHEM Conference on Hetreocycles in Bio-organic Chemistry, Sitges (Barcelona), Spain; 09.06.2002 - 12.06.2002; abstract published in: Eleventh FECHEM Conference on Hetreocycles in Bio-organic Chemistry 2002, pp.18 - 19.
J. Fröhlich, U. Jordis, M. Hemetsberger, L. Czollner, B. Küenburg.
The Galanthamine Story: from Milligrams to Kilograms - from the Natural Compound to New Lead Structures for Alzheimer Treatment. Oral presentation at the 1st International SPECS and BioSPECS Symposium, Delft, Niederlande; 18.09.2002 - 21.09.2002; abstract published in: The 1st International SPECS and BioSPECS Symposium 2002, pp. 30 - 32.
J. Fröhlich, U. Jordis, M. Hemetsberger, M. Treu, B. Küenburg.
The Synthesis of Galanthamine, an Alzheimer Drug, and Novel Rescaffolding Derivatives thereof. Oral presentation at the 9th Ibn Sina International Conference On Pure and Applied Heterocyclic Chemistry, Sharm El-Sheik, Egypt (invited); 11.12.2004 - 14.12.2004; abstract published in: 9th ISCHC - Book of Abstracts 2004.
J. Fröhlich, U. Jordis, M. Hemetsberger, L. Czollner, B. Küenburg.
A Novel Alzheimer Therapeutic: Galanthamine, An Amaryllidaceae Alkaloid - Its Technical Synthesis And Novel Derivatives. Oral presentation at the 4th National Meeting of Organic Chemistry, Coimbra, Portugal; 26.09.2001 - 28.09.2001.
PhD Thesis
M. Hemetsberger.
Synthese neuer substituierter und anellierter Galanthaminderivate. 1999
References
- Amgen Austria GmbH, Vienna, Austria
- Amgen Central and Eastern Europe Headquarters, Vienna, Austria
- Amgen Ltd., Uxbridge, UK
- Amgen Switzerland AG, Zug, Switzerland
- Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
- CECOG, Vienna, Austria
- Celgene GmbH, Vienna, Austria
- EBG MedAustron GmbH, Wiener Neustadt, Austria
- Germania Pharmazeutika GmbH, Vienna, Austria
- GlaxoSmithKline Kft., Budapest, Hungary
- Kantonsspital St. Gallen, Switzerland
- Medical University of Graz, Austria
- Medical University of Innsbruck, Austria
- Medical University of Vienna, Austria
- MorphoSys AG, Martinsried/Planegg, Germany
- PharmaMar GmbH, Vienna, Austria
- Supplexan, Mödling, Austria
- Wilhelminen Krebsforschung GmbH, Vienna, Austria
Testimonials
"Dr Margit Hemetsberger is a most reliable and my preferred partner in developing scientific abstracts, posters and manuscripts. Additional services include the coordination of approval processes, writing summaries and flash reports, as well as providing training for new staff, and Medical Information/Communication services. What makes working with her so easy is the high quality she delivers – reliably and on time."
Christine Jäger, Medical Leader, Amgen (Austria) GmbH
"Dr. Margit Hemetsberger is a most competent partner in supporting our company with either medical writing support, coordinating clinical study publications or delivering high quality medical trainings. We are always very satisfied with her work that is delivered on time and are looking forward for our next projects we will execute together."
Erich Durchschlag, Medical Leader, Amgen (Austria) GmbH
"Margit has extremely successfully managed complex international medical communications projects, such as major stand alone educational events on complex topics in nephrology, satellite symposia at major European Medical conferences, and generation of impactful slide decks and other tools for regional medical liaisons. Both scientific quality and managerial execution were impressive. I can highly recommend Margit for projects requiring analytical skills and scientific expertise. She is great in translating complex data into key conclusions and messages."
Martin Wright, PhD, Director, Head Medical Communication and Medical Information, Amgen (Europe) GmbH
"Margit is a dedicated and determined project manager who ensures the project gets done to a high degree of quality. She also has a wonderful writing style. Her thoughtful and analytical approach to her colleagues and customers makes her an excellent communicator by bringing about full engagement in scientific, as well as, practical issues."
Carolyn Heath, Associate Counsel, Amgen (Europe) GmbH
Reviewer Comments
"Excellent paper, very well written and covers all relevant features. […] I have no doubt it will be quoted. "
A referee
[…] Based on the fact that this was a non-interventional study the data are presented in adequate detail and clarity and the interpretation is cautious. Hence I do not have any suggestions for improvement […]
↑
Experience & Skills
Background
As a PhD in organic chemistry, I have a solid background in the natural sciences and have done research of my own. My job history has taken me through various stages of drug development and through different science communication jobs.
My skills have been developed during 15 years of working for universities, the pharmaceutical and biotechnology industries, the Swiss health authorities, and as a freelancer. I have also co-founded a pharma-start-up.
My personal experience extends over several scientific areas, such as oncology and hematology, nephrology, neurology, immunology, chemistry, veterinary medicine, and technical skills, such as papers, patents, protocols, training, competitive intelligence, public health.
I’ll be happy to dig into any new field!
- 02/2009 to date: Medical writing, scientific communication and training, consultancy
- 03/2008 – 01/2009: Federal Office for Public Health in Berne (CH) / Scientific Officer (Influenza Vaccine Promotion)
- 05/2005 – 11/2007: Amgen International in Zug (CH) / Medical Communications Senior Manager
- 04/2002 – 04/2005: Amgen (Austria) GmbH in Vienna (A) / Medical Information and Communications Manager
- 06/2001 – 03/2002: sabbatical break
- 12/2000 – 06/2001: Berolina Drug Development AB in Svedala (S) / Chief Project Management Officer
- 10/1999 – 11/2000: Sanochemia Pharmazeutika AG in Vienna (A) / Preclinical Drug Development & Intellectual Property Management
- 01/1999 – 06/1999: Vienna University of Technology in Vienna (A) / Associate Teacher in Organic Chemistry
- Medical and scientific writing for companies and research groups
- Medical communications, information, and training at international headquarter and local affiliate level in leading biotechnology firm
- Development of strategic medical communication plans and budgets as a component of brand- and medical affairs plans
- Organization of congress based industry symposia, stand-alone symposia, advisory boards, and speakers training workshops
- Relationship management with key opinion leaders, as well as business partners and investors
- Scientific congress reporting and competitive intelligence
- Leadership experience with direct reports and cross-functional project teams
- Certified trainer, experienced in developing training materials and providing product and therapeutic area training to sales and medical affairs staff
- Health promotion and social change management in the public health sector
Languages
- German: native language
- English: excellent command in oral and writing, including technical, business, and medical terminology
- French: good command of the language in oral and writing
- Spanish: fluent in oral and writing
↑
Cooperations
A network of experienced colleagues is available to meet your special demands. Additional medical writers can be brought in for projects that are too big for one. An english native speaker will edit texts upon request. A graphic designer is available to provide graphics, layout and print.
Dr. Eva Müller, Scientific Writer
Eva Müller is a Ph.D. biologist with many years of practical experience in scientific research and scientific writing. Today she works as a freelance science writer and writes publications, research and project reports for biotechnology and pharmaceutical companies as well as for research institutes. In addition, she teaches scientific writing at national and international universities, research centers, and hospitals and individually coaches scientists in writing scientific publications.
→ www.lifescience-texte.de
Julia Balfour BSc (Hons), MR Pharm S, Freelance Medical Writer/Consultant
Originally trained as a hospital pharmacist in Edinburgh, UK; 20+ years’ experience in UK, Switzerland, New Zealand and Australia as a medical writer with publications group (Adis International), pharma industry and freelance; >50 publications under own name in PubMed. Native English speaker, since 2007 providing high-quality medical writing and editing services directly to a group of clients that includes academic research groups, health economics specialists and pharma industry.
→ www.northstarmedwrite.com
Mag. Ulrike Posch, Scientific Author
First class microbiology degree at the University of Innsbruck with a special focus on biochemistry and immunology. Several months project work at the Institute for Medical Chemistry and Biochemistry, as well as a two-year scientific assignment at the Institute for Hygiene and Social Medicine at the University of Innsbruck, provided me with a thorough understanding of analytical processes, method development, cell culture techniques and BSL-3-HIV-laboratory. It also provided me with a thorough training in scientific work processes and science writing. 2002 Graduation with honors. Professional experience within the pharmaceutical industry included GLP/GMP for pharmaceutical product development, as well as customer support as a product specialist for the pharmaceutical sales force. Freelancing scientific writer since 2008. Relevant further training at CfPIE (Berlin) and KKS (University of Innsbruck), amongst others, have further solidified the writing expertise already gained by working as a professional science writer within a multitude of different scientific and medical areas.
→ www.sciencewriting.at
Maria Weinhofer, Graphic Designer
Self-employed graphic designer, webdesigner and illustrator since 2007. Main focus on ecologically friendly graphic design.
Logo & Corporate Design, brochures, flyers, posters, calendars, websites, illustrations, etc
→ www.grafikmanufaktur.at
↑
